Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, womenâs health, cardiovascular, and respiratory disease.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSEPN
āļāļ·āđāļāļāļĢāļīāļĐāļąāļSepterna Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 25, 2024
āļāļĩāļāļĩāđāļFiner (Jeffrey)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ75
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 25
āļāļĩāđāļāļĒāļđāđ250 East Grand Avenue, Suite 65
āđāļĄāļ·āļāļSOUTH SAN FRANCISCO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ94080
āđāļāļĢāļĻāļąāļāļāđ16503383533
āđāļ§āđāļāđāļāļāđhttps://septerna.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSEPN
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 25, 2024
āļāļĩāļāļĩāđāļFiner (Jeffrey)
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
Ms. Elizabeth P. (Liz) Bhatt
Ms. Elizabeth P. (Liz) Bhatt
President
Dr. Uwe Klein, Ph.D.
Senior Vice President - Biological Sciences
Senior Vice President - Biological Sciences
Dr. Alan Ezekowitz, M.D., Ph.D.
Dr. Alan Ezekowitz, M.D., Ph.D.
Director
Ms. Samira Shaikhly
Chief People Officer
Mr. Daniel (Dan) Long
Senior Vice President - Drug Discovery
Senior Vice President - Drug Discovery
Dr. Jeffrey K. (Jeff) Tong, Ph.D.
Dr. Jeffrey K. (Jeff) Tong, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Jae B. Kim, M.D.
Chief Medical Officer
Mr. Abraham (Abe) Bassan
Independent Director
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
Ms. Elizabeth P. (Liz) Bhatt
Ms. Elizabeth P. (Liz) Bhatt
President
Dr. Uwe Klein, Ph.D.
Senior Vice President - Biological Sciences
Senior Vice President - Biological Sciences
Dr. Alan Ezekowitz, M.D., Ph.D.
Dr. Alan Ezekowitz, M.D., Ph.D.
Director
Ms. Samira Shaikhly
Chief People Officer
Mr. Daniel (Dan) Long
Senior Vice President - Drug Discovery
Senior Vice President - Drug Discovery